Department of Nanomedicine, Houston Methodist Research Institute, USA
Mini Review
Determine Tumor Site-Dependent Transport Properties Delivery of
Nanotherapeutics and Their Efficacy
Author(s): Pranav Shende*
Therapeutic effectiveness of anticancer medicines delivered systemically may be hampered by insufficient distribution of the medications to tumours. Can create therapeutic resistance based on drug delivery. PEGylated liposomal doxorubicin (PLD), for example, uses an increased permeability and retention effect to preferentially accumulate in tumours. Their clinical results and anticancer effects, however, vary widely amongst tumour types and are minimal. We looked into whether the tumour site affected the quantity and effectiveness of PLD delivered to tumours. We created mouse breast models with orthotopic primary tumours or liver metastases. Utilising 4 T1 cells for cancer PLD effectively treated cancers that developed in primary mammary tissue. but not in the liver, locations. We discovered that variations in treatment effectiveness were not caused by the intrinsic biological defence.. View more»